Prokarium

21 articles about Prokarium

• Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial

  2/7/2024

  Prokarium today announces the dosing of the first patient in their PARADIGM-1 Phase I/Ib clinical trial in non-muscle invasive bladder cancer (NMIBC) patients (NCT06181266).

• Prokarium Achieves Major Milestone with FDA's IND Approval for Bladder Cancer Program

  11/2/2023

  Prokarium announces that the U.S. Food and Drug Administration has granted the company's Investigational New Drug application for their immunotherapy ZH9.

• Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform

  2/9/2023

  Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has raised $30 million in new funding.

• Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies

  10/5/2022

  Prokarium Ltd, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced the receipt of a Notice of Allowance from the United States Patent and Trademark Office.

• Prokarium Exercises Option for an Exclusive Worldwide License for the Use of Salmonella Immunotherapy in the Treatment of Bladder Cancer

  3/2/2022

  Prokarium announced it exercised its option with Lausanne University Hospital for an exclusive, worldwide license for the use of Salmonella immunotherapy in the treatment of bladder cancer.

• Prokarium Expands R&D Capabilities with London Biofoundry to Deepen Microbial Immunotherapy Pipeline

  1/26/2022

  Prokarium has entered into an agreement, through Imperial Projects, to work with independent researchers from Imperial College London to develop Prokarium’s next-generation therapeutic candidates, engineered to deliver payloads within the tumor microenvironment.

• Prokarium Shares Preclinical Proof-of-Concept Data on Its Microbial Immunotherapy Bladder Cancer Program at SITC 2021

  11/11/2021

  Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, shared preclinical data at the Society for Immunotherapy of Cancer’s 36th Annual Meeting.

• Prokarium Promotes Livija Deban to Chief Scientific Officer to Drive Pipeline Expansion in Cancer Immunotherapy

  11/2/2021

  Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced the appointment of Livija Deban, PhD, as Chief Scientific Officer.

• Prokarium Appoints Industry Veteran Thomas Eldered as Chairman of the Board

  10/5/2021

  Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced the appointment of Thomas Eldered as Chairman of the Board.

• 

  BioSpace Movers & Shakers, July 30, 2021

  7/30/2021

  Biopharma and life science companies strengthen their leadership teams and boards with these Movers & Shakers.

• Prokarium Appoints Uz Stammberger as Chief Medical Officer to Drive Clinical Development in Oncology

  7/29/2021

  Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced the appointment of Uz Stammberger, MD, as Chief Medical Officer.

• Prokarium Appoints Kristen Albright as Chief Executive Officer

  7/27/2021

  Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced the appointment of Kristen Albright, PharmD, as Chief Executive Officer.

• 

  Biopharma Money on the Move: October 21-27

  10/28/2020

  Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

• Prokarium Closes $21M Series B Financing Round and Strengthens Board

  10/27/2020

  Financing will support the clinical development of Prokarium’s microbial immunotherapy for non-muscle invasive bladder cancer as well as expansion of pipeline across multiple solid tumours

• Prokarium Signs an Exclusive Option Agreement with the Lausanne University Hospital (Centre Hospitalier Universitaire Vaudois - CHUV) for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

  4/28/2020

  Prokarium is pleased to announce it has signed an exclusive, worldwide Option Agreement with the Lausanne University Hospital - CHUV, a Switzerland-based research hospital, to acquire a license to cover the treatment of Non-Muscle Invasive Bladder Cancer patients with intravesical instillations of Salmonella.

• Prokarium Announces MHRA Acceptance to Run Phase I Trial of Lead Vaccine Against Enteric Fever

  11/26/2019

  Prokarium, a private biotechnology company developing vaccines against infectious diseases and immunotherapy for solid tumors, has received Clinical Trial Authorization (CTA) acceptance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to run a first-in-human Phase I trial with Entervax™, a bivalent vaccine against enteric fever

• Prokarium Announces MHRA Acceptance to Run Phase I Trial of Lead Vaccine Against Enteric Fever

  11/26/2019

  Prokarium, a private biotechnology company developing vaccines against infectious diseases and immunotherapy for solid tumors, has received Clinical Trial Authorization acceptance from the UK Medicines and Healthcare products Regulatory Agency to run a first-in-human Phase I trial with Entervax™, a bivalent vaccine against enteric fever.

• Prokarium Secures £4.6M from Wellcome to Fund the Clinical Development of its Lead Vaccine Programme

  10/8/2019

  Prokarium announced it has received an investment of £4.59 million from Wellcome to fund two clinical trials of its lead programme, Entervax™, a bivalent vaccine against enteric fever.

• Prokarium Secures $10 Million Investment from Saudi, Swedish and Korean Investors for Clinical Development of Revolutionary Thermostable Vaccines

  2/26/2018

  The new funds will enable the clinical development of groundbreaking vaccines against Chlamydia, C.difficile and enteric fever (typhoid and paratyphoid), as well as expansion of the team for R&D in immuno-oncology.

• Prokarium And Probiomed In UK-Mexico Collaboration To Scale-Up Manufacture Of Thermostable Vaccines With A Focus On Diarrhea

  1/4/2017